Hurdles in bacteriophage therapy: Deconstructing the parameters

Veterinary Microbiology

Volumn 171, Issue 3-4, 2014, Pages 460-469

  Tsonos, Jessica ^a,b   Vandenheuvel, Dieter ^b   Briers, Yves ^b   De Greve, Henri ^a   Hernalsteens, Jean Pierre ^a   Lavigne, Rob ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b LABORATORY OF GENE TECHNOLOGY   (Belgium)

Author keywords

Phage kinetics; Phage therapy; Phage translocation; State of bacteria in vivo

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOPHAGE RECEPTOR; ANTIINFECTIVE AGENT; VIRUS RECEPTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; DRUG DELIVERY SYSTEM; ENVIRONMENTAL PARAMETERS; GENE CONTROL; HOST RANGE; IN VITRO STUDY; IN VIVO STUDY; MORBIDITY; PATHOGENESIS; PHAGOCYTOSIS; PSEUDOMONAS INFECTION; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; UPREGULATION; ANIMAL; BACTERIAL INFECTIONS; BACTERIOLYSIS; BIOLOGICAL THERAPY; CATERING SERVICE; FEMALE; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES; TRENDS; VETERINARY; VIRAL TROPISM; VIROLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOLYSIS; BACTERIOPHAGES; BIOLOGICAL THERAPY; FEMALE; FOOD SUPPLY; RECEPTORS, VIRUS; VIRAL TROPISM;

EID: 84901924945     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2013.11.001     Document Type: Article

References (66)

1. Abedon S. Phage therapy pharmacology: calculating phage dosing. Adv. Appl. Microbiol. 2011, 77:1-40.
2. Angelichio M.J., Camilli A. In vivo expression technology. Infect. Immun. 2002, 70:6518-6523.
3. Bardina C., Spricigo D.A., Cortés P., Llagostera M. Significance of the bacteriophage treatment schedule in reducing Salmonella colonization of poultry. Appl. Environ. Microbiol. 2012, 78:6600-6607.
4. Barrow P., Lovell M., Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin. Diagn. Lab. Immunol. 1998, 5:294-298.
5. Barrow P.A., Soothill J.S. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 1997, 5:268-271.
6. Bogomolnaya L.M., Santiviago C.A., Yang H.J., Baumler A.J., Andrews-Polymenis H.L. 'Form variation' of the O12 antigen is critical for persistence of Salmonella typhimurium in the murine intestine. Mol. Microbiol. 2008, 70:1105-1119.
7. Broxmeyer L., Sosnowska D., Miltner E., Chacón O., Wagner D., McGarvey J., Barletta R.G., Bermudez L.E. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J. Infect. Dis. 2002, 186:1155-1160.
8. Brüssow H. Phage therapy: the Escherichia coli experience. Microbiology 2005, 151:2133-2140.
9. Bull J.J., Levin B.R., DeRouin T., Walker N., Bloch C.A. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2002, 2:35.
10. Cairns B.J., Timms A.R., Jansen V.A., Connerton I.F., Payne R.J. Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathog. 2009, 5:e1000253.
11. Capparelli R., Parlato M., Borriello G., Salvatore P., Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 2007, 51:2765-2773.
12. Carmody L.A., Gill J.J., Summer E.J., Sajjan U.S., Gonzalez C.F., Young R.F., LiPuma J.J. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 2010, 201:264-271.
13. Carvalho C., Santos S., Kropinski A., Ferreira E., Azeredo J. Phages as therapeutic tools to control major foodborne pathogens: Campylobacter and Salmonella. Bacteriophages 2012, 179-214. InTech, Rijeka. D.I. Kurtboke (Ed.).
14. Cerveny K.E., DePaola A., Duckworth D.H., Gulig P.A. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect. Immun. 2002, 70:6251-6262.
15. Courchesne N.M., Parisien A., Lan C.Q. Production and application of bacteriophage and bacteriophage-encoded lysins. Recent Pat. Biotechnol. 2009, 3:37-45.
16. Curtright A.J., Abedon S.T. Phage therapy: emergent property pharmacology. J. Bioanal. Biomed. 2011, S6:002.
17. Duerr D.M., White S.J., Schluesener H.J. Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J. Virol. Methods 2004, 116:177-180.
18. FAO Food and Agricultural Organization of the United Nations 2013, World Food and Agriculture, Rome.
19. Finlay B.B., Falkow S. Common themes in microbial pathogenicity. Microbiol. Rev. 1989, 53:210-230.
20. Fiorentin L., Vieira N.D., Barioni W. Oral treatment with bacteriophages reduces the concentration of Salmonella Enteritidis PT4 in caecal contents of broilers. Avian Pathol. 2005, 34:258-263.
21. Fischetti V.A., Nelson D., Schuch R. Reinventing phage therapy: are the parts greater than the sum?. Nat. Biotechnol. 2006, 24:1508-1511.
22. Hagens S., Loessner M.J. Listeria monocytogenes: Pathogenesis and Host Response 2007, Springer, US.
23. Hanlon G.W. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob. Agents 2007, 30:118-128.
24. Hawkins C., Harper D., Burch D., Anggård E., Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet. Microbiol. 2010, 146:309-313.
25. Henry M., Lavigne R., Debarbieux L. Predicting in vivo efficacy to guide the choice of therapeutic bacteriophages to treat pulmonary infections. Antimicrob. Agents Chemother. 2013, 57:5961-5968.
26. Hermoso J.A., García J.L., García P. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr. Opin. Microbiol. 2007, 10:461-472.
27. Hsia R., Ohayon H., Gounon P., Dautry-Varsat A., Bavoil P.M. Phage infection of the obligate intracellular bacterium. Chlamydia psittaci strain guinea pig inclusion conjunctivitis. Microbes Infect. 2000, 2:761-772.
28. Huff W.E., Huff G.R., Rath N.C., Balog J.M., Donoghue A.M. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult. Sci. 2003, 82:1108-1112.
29. Inal J.M. Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch. Immunol. Ther. Exp. (Warsz) 2003, 51:237-244.
30. Jamalludeen N., Johnson R.P., Shewen P.E., Gyles C.L. Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet. Microbiol. 2009, 136:135-141.
31. Jamalludeen N., She Y.M., Lingohr E.J., Griffiths M. Isolation and characterization of virulent bacteriophages against Escherichia coli serogroups O1, O2, and O78. Poult. Sci. 2009, 88:1694-1702.
32. Keller R., Engley F.B. Fate of bacteriophage particles introduced into mice by various routes. Proc. Soc. Exp. Biol. Med. 1958, 98:577-580.
33. Kim M., Ryu S. Spontaneous and transient defence against bacteriophage by phase-variable glucosylation of O-antigen in Salmonella enterica serovar Typhimurium. Mol. Microbiol. 2012, 86:411-425.
34. Kutateladze M., Adamia R. Phage therapy experience at the Eliava Institute. Med. Mal. Infect. 2008, 38:426-430.
35. Kvachadze L., Balarjishvili N., Meskhi T., Tevdoradze E., Skhirtladze N., Pataridze T., Adamia R., Topuria T., Kutter E., Rohde C., Kutateladze M. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb. Biotechnol. 2011, 4:643-650.
36. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2004, 2:166-173.
37. Lindberg A.A. Bacteriophage receptors. Annu. Rev. Microbiol. 1973, 27:205-241.
38. Loc-Carrillo C., Abedon S.T. Pros and cons of phage therapy. Bacteriophage 2011, 1:111-114.
39. Mahan M.J., Heithoff D.M., Sinsheimer R.L., Low D.A. Assessment of bacterial pathogenesis by analysis of gene expression in the host. Annu. Rev. Genet. 2000, 34:139-164.
40. Mandrell R.E., Lesse A.J., Sugai J.V., Shero M., Griffiss J.M., Cole J.A., Parsons N.J., Smith H., Morse S.A., Apicella M.A. In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation. J. Exp. Med. 1990, 171:1649-1664.
41. Markoishvili K., Tsitlanadze G., Katsarava R., Morris J.G., Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 2002, 41:453-458.
42. Marza J.A., Soothill J.S., Boydell P., Collyns T.A. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 2006, 32:644-646.
43. McCallin S., Alam Sarker S., Barretto C., Sultana S., Berger B., Huq S., Krause L., Bibiloni R., Schmitt B., Reuteler G., Brussow H. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 2013, 443:187-196.
44. Miernikiewicz P., Dabrowska K., Piotrowicz A., Owczarek B., Wojas-Turek J., Kicielinska J., Rossowska J., Pajtasz-Piasecka E., Hodyra K., Macegoniuk K., Rzewucka K., Kopciuch A., Majka T., Letarov A., Kulikov E., Maciejewski H., Gorski A. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS ONE 2013, 8:e71036.
45. Neuman W. Cargill Issues Meat Recall after Turkey Tied to Illness 2011, In The New York Times, New York, (August 4).
46. Neushul P. Science, government, and the mass production of penicillin. J. Hist. Med. Allied Sci. 1993, 48:371-395.
47. Oliveira A., Sereno R., Nicolau A., Azeredo J. The influence of the mode of administration in the dissemination of three coliphages in chickens. Poult. Sci. 2009, 88:728-733.
48. Payne R.J., Jansen V.A. Understanding bacteriophage therapy as a density-dependent kinetic process. J. Theor. Biol. 2001, 208:37-48.
49. Payne R.J., Jansen V.A. Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet. 2003, 42:315-325.
50. Payne R.J., Phil D., Jansen V.A. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin. Pharmacol. Ther. 2000, 68:225-230.
51. Petty N.K., Evans T.J., Fineran P.C., Salmond G.P. Biotechnological exploitation of bacteriophage research. Trends Biotechnol. 2007, 25:7-15.
52. Rakhuba D.V., Kolomiets E.I., Dey E.S., Novik G.I. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol. J. Microbiol. 2010, 59:145-155.
53. Rosenquist H., Nielsen N.L., Sommer H.M., Nørrung B., Christensen B.B. Quantitative risk assessment of human campylobacteriosis associated with thermophilic Campylobacter species in chickens. Int. J. Food Microbiol. 2003, 83:87-103.
54. Scholl D., Adhya S., Merril C. Escherichia coli K1's capsule is a barrier to bacteriophage T7. Appl. Environ. Microbiol. 2005, 71:4872-4874.
55. Smith H.W., Huggins M.B. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 1982, 128:307-318.
56. Snyder J.A., Haugen B.J., Buckles E.L., Lockatell C.V., Johnson D.E., Donnenberg M.S., Welch R.A., Mobley H.L. Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect. Immun. 2004, 72:6373-6381.
57. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov. Today 2005, 10:807-809.
58. Summers W.C. Bacteriophage therapy. Annu. Rev. Microbiol. 2001, 55:437-451.
59. Tuntufye H.N., Lebeer S., Gwakisa P.S., Goddeeris B.M. Identification of Avian pathogenic Escherichia coli genes that are induced in vivo during infection in chickens. Appl. Environ. Microbiol. 2012, 78:3343-3351.
60. Verbeken G., Pirnay J.P., De Vos D., Jennes S., Zizi M., Lavigne R., Casteels M., Huys I. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp. (Warsz) 2012, 60:161-172.
61. Verthé K., Possemiers S., Boon N., Vaneechoutte M., Verstraete W. Stability and activity of an Enterobacter aerogenes-specific bacteriophage under simulated gastro-intestinal conditions. Appl. Microbiol. Biotechnol. 2004, 65:465-472.
62. Wagenaar J.A., Van Bergen M.A., Mueller M.A., Wassenaar T.M., Carlton R.M. Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet. Microbiol. 2005, 109:275-283.
63. Wagner P.L., Waldor M.K. Bacteriophage control of bacterial virulence. Infect. Immun. 2002, 70:3985-3993.
64. Weber-Dabrowska B., Mulczyk M., Gorski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch. Immunol. Ther. Exp. (Warsz) 2000, 48:547-551.
65. Weber-Dabrowska B., Mulczyk M., Gorski A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc. 2003, 35:1385-1386.
66. Weld R.J., Butts C., Heinemann J.A. Models of phage growth and their applicability to phage therapy. J. Theor. Biol. 2004, 227:1-11.